AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
Nasal Flu Vaccine Is Approved for At-Home Use
The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...
FierceBiotech10h
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
AstraZeneca falls Monday, underperforms market
AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
Here’s Why AstraZeneca PLC (AZN) Surged in Q2
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...
AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance
AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab ...
Business Insider16h
AstraZeneca’s Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial Results
James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the final ...